Lab service utilizes Envision Science's proprietary biomarkers and technology with a goal of improving diagnosis and grading of prostate cancer The new, tissue-based test service is intended to ...

The Food and Drug Administration recently approved the IsoPSA blood test, which was developed by Cleveland Diagnostics, a ...

Grade group 1 prostate cancer assessment should include PSA, stage, and disease volume for accurate risk evaluation. Active surveillance is safe for most low-risk patients, but higher-risk features ...

Prostate cancer is the most common cancer among men after skin cancer. Age is a significant risk factor for prostate cancer. Family history and genetic factors play a significant role in prostate ...

GG1 prostate cancer can have heterogeneous outcomes, with some patients having intermediate- or high-risk disease, challenging the notion of GG1 as uniformly low-risk. Removing the cancer label for ...

Holly has a degree in Medical Biochemistry from the University of Leicester. Her scientific interests include genomics, personalized medicine, and bioethics.View full profile Holly has a degree in ...

A genetic test developed by researchers at Broad Clinical Labs and the U.S. Department of Veterans Affairs (VA) is now enabling a large, nationwide clinical trial aimed at improving health care for ...

As we gear up to observe World Cancer Day 2026 under the theme 'United by Unique', let's take a look at the stages of ...

Former President Joe Biden has been diagnosed with an "aggressive" form of prostate cancer that has spread to his bones. But what does it mean for this type of cancer to be called aggressive? As a ...